Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 225-232

  Luporsi, Elisabeth ^a   Mahi, Lamine ^b   Morre, Camille ^c   Wernli, Jorge ^b   De Pouvourville, Gérard ^d   Bugat, Roland ^e  

^a INSERM   (France)

^b Vifor (International) Inc   (Switzerland)

^c JNBD Développement   (France)

^d ESSEC BUSINESS SCHOOL   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Anemia; Erythropoiesis stimulating agents; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRIC CARBOXYMALTOSE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PROTOCOL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG DOSE REGIMEN; ECONOMIC EVALUATION; FRANCE; HEALTH CARE COST; HIP SURGERY; HUMAN; IRON DEFICIENCY ANEMIA; KNEE SURGERY; PERIOPERATIVE ANEMIA; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANEMIA; BLOOD TRANSFUSION; COST SAVINGS; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; FEMALE; FERRIC COMPOUNDS; FRANCE; HEMATINICS; HUMANS; MALTOSE; MODELS, ECONOMIC;

EID: 84858129582     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.639823     Document Type: Article

References (36)

1. Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56 (Pubitemid 40525376)
2. Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005;11:565-74
3. Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005;8:629-38 (Pubitemid 43110277)
4. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95 (Pubitemid 30010408)
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34 (Pubitemid 29479929)
6. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25:2-6 (Pubitemid 28326216)
7. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001;19:19-30 (Pubitemid 32267844)
8. Spielmann M, Luporsi E, Ray-Coquard I, et al. Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: The AnemOnHe study. Eur J Cancer in press
9. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999;81:2-10 (Pubitemid 29068441)
10. Feagan BG, Wong CJ, Lau CY, et al. Transfusion practice in elective orthopaedic surgery. Transfus Med 2001;11:87-95 (Pubitemid 32455659)
11. Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003;43:459-69 (Pubitemid 36428328)
12. Bong MR, Patel V, Chang E, et al. Risks associated with blood transfusion after total knee arthroplasty. J Arthroplasty 2004;19:281-7 (Pubitemid 38519818)
13. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14 (Pubitemid 32816195)
14. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 2010;50:719-32
15. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69:739-56
16. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16 (Pubitemid 39348870)
17. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70 (Pubitemid 46127840)
18. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7 (Pubitemid 41079845)
19. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26:1619-25
20. Cuenca J, Garcia-Erce JA, Martinez AA, et al. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005;125:342-7 (Pubitemid 40895356)
21. Cuenca J, Garcia-Erce JA, Munoz M, et al. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion 2004;44:1447-52 (Pubitemid 39318979)
22. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-8
23. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist 2007; 12:231-42
24. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-32 (Pubitemid 46444544)
25. Institut National de Veille Sanitaire. Evolution de l'incidence et de la mortalité par cancer en France de 1980 à 2005. Fiche: sein. 30 Janvier 2008. Estimations à partir des donné es des registres du ré seau FRANCIM et du CepiDC. http://www.invs.sante.fr/surveillance/ cancers/mortalite-1980-2005/donnees-localisation/sein/sein.pdf. Accessed November 21, 2011
26. Haute Autorité de Santé . Commission de la transparence. Taxotè re. Avis du 15 Fé vrier 2006. http://www.has-sante.fr/ portail/upload/docs/application/pdf/ct032531.pdf. Accessed November 21, 2011
27. Institut de Veille Sanitaire. Bulletin Epidé miologique Hebdomadaire. Numé ro thé matique-Dé pistage organisé du cancer colorectal en France. n-2-3. 13 January 2009, Paris
28. Bouvier AM, Remontet L, Jougla E, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004;28:877-81 (Pubitemid 39422865)
29. Schneider M. Fré quence de l'ané mie chez les patients franç ais atteints de tumeurs solides ou d'hé mopathies malignes: ré sultats de l' "European Cancer Anaemia Survey (ECAS)". Oncologie 2005;7:397-702
30. Rodgers et al. Cancer-and Chemotherapy-induced anemia. Clinical Practice Guidelines in Oncology. Version 2. 2012. National Comprehensive Cancer Network (NCCN), United States. http://www.nccn.org/professionals/physician-gls/pdf/ anemia.pdf. Accessed November 21, 2011
31. Auerbach M. New intravenous iron replacement therapies. Clin Adv Hematol Oncol 2010;8:688-9
32. Pigeon M, Courtois J, Rigollot N and Samson S. Les mé dicaments les plus prescrits en France. Consensus Cardio 47, March 2009. http://www.consensus-online.fr/spip.php?article323. Accessed November 23, 2011
33. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-15
34. Steiner S, Brock E, Schneider H. Budget impact of parenteral iron treatment of iron deficiency anaemia in Switzerland. Abstract no. PHM2. Value Health 2007;10:A280
35. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008;26:1579-81
36. Hedenus M, Nasman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008;33:365-74